The therapeutic landscape of HIV-1 via genome editing.
Identifieur interne : 000571 ( PubMed/Corpus ); précédent : 000570; suivant : 000572The therapeutic landscape of HIV-1 via genome editing.
Auteurs : Alexander Kwarteng ; Samuel Terkper Ahuno ; Godwin Kwakye-NuakoSource :
- AIDS research and therapy [ 1742-6405 ] ; 2017.
Abstract
Current treatment for HIV-1 largely relies on chemotherapy through the administration of antiretroviral drugs. While the search for anti-HIV-1 vaccine remain elusive, the use of highly active antiretroviral therapies (HAART) have been far-reaching and has changed HIV-1 into a manageable chronic infection. There is compelling evidence, including several side-effects of ARTs, suggesting that eradication of HIV-1 cannot depend solely on antiretrovirals. Gene therapy, an expanding treatment strategy, using RNA interference (RNAi) and programmable nucleases such as meganuclease, zinc finger nuclease (ZFN), transcription activator-like effector nuclease (TALEN), and clustered regularly interspaced short palindromic repeats/CRISPR-associated proteins (CRISPR-Cas9) are transforming the therapeutic landscape of HIV-1. TALENS and ZFNS are structurally similar modular systems, which consist of a FokI endonuclease fused to custom-designed effector proteins but have been largely limited, particularly ZFNs, due to their complexity and cost of protein engineering. However, the newly developed CRISPR-Cas9 system, consists of a single guide RNA (sgRNA), which directs a Cas9 endonuclease to complementary target sites, and serves as a superior alternative to the previous protein-based systems. The techniques have been successfully applied to the development of better HIV-1 models, generation of protective mutations in endogenous/host cells, disruption of HIV-1 genomes and even reactivating latent viruses for better detection and clearance by host immune response. Here, we focus on gene editing-based HIV-1 treatment and research in addition to providing perspectives for refining these techniques.
DOI: 10.1186/s12981-017-0157-8
PubMed: 28705213
Links to Exploration step
pubmed:28705213Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The therapeutic landscape of HIV-1 via genome editing.</title><author><name sortKey="Kwarteng, Alexander" sort="Kwarteng, Alexander" uniqKey="Kwarteng A" first="Alexander" last="Kwarteng">Alexander Kwarteng</name><affiliation><nlm:affiliation>Department of Biochemistry and Biotechnology, Kwame Nkrumah University of Science and Technology (KNUST), PMB, Kumasi, Ghana. akwarteng@knust.edu.gh.</nlm:affiliation></affiliation></author><author><name sortKey="Ahuno, Samuel Terkper" sort="Ahuno, Samuel Terkper" uniqKey="Ahuno S" first="Samuel Terkper" last="Ahuno">Samuel Terkper Ahuno</name><affiliation><nlm:affiliation>Department of Biochemistry and Biotechnology, Kwame Nkrumah University of Science and Technology (KNUST), PMB, Kumasi, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Kwakye Nuako, Godwin" sort="Kwakye Nuako, Godwin" uniqKey="Kwakye Nuako G" first="Godwin" last="Kwakye-Nuako">Godwin Kwakye-Nuako</name><affiliation><nlm:affiliation>Department of Biomedical Sciences, School of Allied Health Sciences, College of Health and Allied Sciences, University of Cape Coast, Cape Coast, Ghana.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28705213</idno><idno type="pmid">28705213</idno><idno type="doi">10.1186/s12981-017-0157-8</idno><idno type="wicri:Area/PubMed/Corpus">000571</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000571</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The therapeutic landscape of HIV-1 via genome editing.</title><author><name sortKey="Kwarteng, Alexander" sort="Kwarteng, Alexander" uniqKey="Kwarteng A" first="Alexander" last="Kwarteng">Alexander Kwarteng</name><affiliation><nlm:affiliation>Department of Biochemistry and Biotechnology, Kwame Nkrumah University of Science and Technology (KNUST), PMB, Kumasi, Ghana. akwarteng@knust.edu.gh.</nlm:affiliation></affiliation></author><author><name sortKey="Ahuno, Samuel Terkper" sort="Ahuno, Samuel Terkper" uniqKey="Ahuno S" first="Samuel Terkper" last="Ahuno">Samuel Terkper Ahuno</name><affiliation><nlm:affiliation>Department of Biochemistry and Biotechnology, Kwame Nkrumah University of Science and Technology (KNUST), PMB, Kumasi, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Kwakye Nuako, Godwin" sort="Kwakye Nuako, Godwin" uniqKey="Kwakye Nuako G" first="Godwin" last="Kwakye-Nuako">Godwin Kwakye-Nuako</name><affiliation><nlm:affiliation>Department of Biomedical Sciences, School of Allied Health Sciences, College of Health and Allied Sciences, University of Cape Coast, Cape Coast, Ghana.</nlm:affiliation></affiliation></author></analytic><series><title level="j">AIDS research and therapy</title><idno type="eISSN">1742-6405</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Current treatment for HIV-1 largely relies on chemotherapy through the administration of antiretroviral drugs. While the search for anti-HIV-1 vaccine remain elusive, the use of highly active antiretroviral therapies (HAART) have been far-reaching and has changed HIV-1 into a manageable chronic infection. There is compelling evidence, including several side-effects of ARTs, suggesting that eradication of HIV-1 cannot depend solely on antiretrovirals. Gene therapy, an expanding treatment strategy, using RNA interference (RNAi) and programmable nucleases such as meganuclease, zinc finger nuclease (ZFN), transcription activator-like effector nuclease (TALEN), and clustered regularly interspaced short palindromic repeats/CRISPR-associated proteins (CRISPR-Cas9) are transforming the therapeutic landscape of HIV-1. TALENS and ZFNS are structurally similar modular systems, which consist of a FokI endonuclease fused to custom-designed effector proteins but have been largely limited, particularly ZFNs, due to their complexity and cost of protein engineering. However, the newly developed CRISPR-Cas9 system, consists of a single guide RNA (sgRNA), which directs a Cas9 endonuclease to complementary target sites, and serves as a superior alternative to the previous protein-based systems. The techniques have been successfully applied to the development of better HIV-1 models, generation of protective mutations in endogenous/host cells, disruption of HIV-1 genomes and even reactivating latent viruses for better detection and clearance by host immune response. Here, we focus on gene editing-based HIV-1 treatment and research in addition to providing perspectives for refining these techniques.</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">28705213</PMID><DateCreated><Year>2017</Year><Month>07</Month><Day>14</Day></DateCreated><DateRevised><Year>2017</Year><Month>07</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1742-6405</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Jul</Month><Day>14</Day></PubDate></JournalIssue><Title>AIDS research and therapy</Title><ISOAbbreviation>AIDS Res Ther</ISOAbbreviation></Journal><ArticleTitle>The therapeutic landscape of HIV-1 via genome editing.</ArticleTitle><Pagination><MedlinePgn>32</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12981-017-0157-8</ELocationID><Abstract><AbstractText>Current treatment for HIV-1 largely relies on chemotherapy through the administration of antiretroviral drugs. While the search for anti-HIV-1 vaccine remain elusive, the use of highly active antiretroviral therapies (HAART) have been far-reaching and has changed HIV-1 into a manageable chronic infection. There is compelling evidence, including several side-effects of ARTs, suggesting that eradication of HIV-1 cannot depend solely on antiretrovirals. Gene therapy, an expanding treatment strategy, using RNA interference (RNAi) and programmable nucleases such as meganuclease, zinc finger nuclease (ZFN), transcription activator-like effector nuclease (TALEN), and clustered regularly interspaced short palindromic repeats/CRISPR-associated proteins (CRISPR-Cas9) are transforming the therapeutic landscape of HIV-1. TALENS and ZFNS are structurally similar modular systems, which consist of a FokI endonuclease fused to custom-designed effector proteins but have been largely limited, particularly ZFNs, due to their complexity and cost of protein engineering. However, the newly developed CRISPR-Cas9 system, consists of a single guide RNA (sgRNA), which directs a Cas9 endonuclease to complementary target sites, and serves as a superior alternative to the previous protein-based systems. The techniques have been successfully applied to the development of better HIV-1 models, generation of protective mutations in endogenous/host cells, disruption of HIV-1 genomes and even reactivating latent viruses for better detection and clearance by host immune response. Here, we focus on gene editing-based HIV-1 treatment and research in addition to providing perspectives for refining these techniques.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kwarteng</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Biotechnology, Kwame Nkrumah University of Science and Technology (KNUST), PMB, Kumasi, Ghana. akwarteng@knust.edu.gh.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR), Kumasi, Ghana. akwarteng@knust.edu.gh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahuno</LastName><ForeName>Samuel Terkper</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Biotechnology, Kwame Nkrumah University of Science and Technology (KNUST), PMB, Kumasi, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwakye-Nuako</LastName><ForeName>Godwin</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, School of Allied Health Sciences, College of Health and Allied Sciences, University of Cape Coast, Cape Coast, Ghana.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>07</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>AIDS Res Ther</MedlineTA><NlmUniqueID>101237921</NlmUniqueID><ISSNLinking>1742-6405</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Gene Ther. 2009 Jan;16(1):148-53</RefSource><PMID Version="1">18668146</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Oligonucleotides. 2003;13(5):303-12</RefSource><PMID Version="1">15000821</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Retrovirology. 2004 Dec 27;1:46</RefSource><PMID Version="1">15620346</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2012 Oct 19;287(43):36609-16</RefSource><PMID Version="1">22952229</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biotechniques. 2006 Apr;Suppl:25-9</RefSource><PMID Version="1">16629384</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Expert Opin Drug Deliv. 2017 Feb;14 (2):245-255</RefSource><PMID Version="1">27426871</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nucleic Acids Res. 2005 Feb 01;33(2):796-804</RefSource><PMID Version="1">15687388</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Virol. 2004 Mar;78(5):2517-29</RefSource><PMID Version="1">14963154</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Ther. 2016 Mar;24(3):522-6</RefSource><PMID Version="1">26796669</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell Res. 2009 Mar;19(3):282-95</RefSource><PMID Version="1">19188930</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Ther. 2011 Dec;19(12):2228-38</RefSource><PMID Version="1">21952167</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 2016 Feb;126(2):415-23</RefSource><PMID Version="1">26752643</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2014 Sep 9;111(36):13151-6</RefSource><PMID Version="1">25157148</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell Cycle. 2013 Feb 1;12 (3):452-62</RefSource><PMID Version="1">23255218</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell Rep. 2016 Apr 19;15(3):481-9</RefSource><PMID Version="1">27068471</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2013 Nov 2;382(9903):1525-33</RefSource><PMID Version="1">24152939</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>FASEB J. 2017 Mar;31(3):975-988</RefSource><PMID Version="1">27881484</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Ther. 2005 Nov;12(5):900-9</RefSource><PMID Version="1">16115802</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2015 Nov 16;10(11):e0142739</RefSource><PMID Version="1">26569506</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet HIV. 2014 Oct;1(1):e13-21</RefSource><PMID Version="1">26423811</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2015 May 06;10(5):e0125652</RefSource><PMID Version="1">25946221</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Biotechnol. 2011 Jul 07;29(8):731-4</RefSource><PMID Version="1">21738127</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Cells. 2016 Sep;39(9):687-91</RefSource><PMID Version="1">27604899</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Sci Rep. 2016 Mar 04;6:22555</RefSource><PMID Version="1">26939770</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Biotechnol. 2008 Jul;39(3):231-8</RefSource><PMID Version="1">18259889</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Virol. 2012 May;86(10):5719-29</RefSource><PMID Version="1">22398281</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Microbiol. 2008 Mar;6(3):181-6</RefSource><PMID Version="1">18157154</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell. 2014 Feb 13;156(4):836-43</RefSource><PMID Version="1">24486104</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>FEBS Lett. 2007 Jul 10;581(17):3253-9</RefSource><PMID Version="1">17592732</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nucleic Acids Res. 2011 Jul;39(12):e82</RefSource><PMID Version="1">21493687</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Elife. 2013 Jan 29;2:e00471</RefSource><PMID Version="1">23386978</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Front Oncol. 2014 Apr 22;4:86</RefSource><PMID Version="1">24795863</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Virol. 2006 Aug;80(15):7658-66</RefSource><PMID Version="1">16840344</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antimicrob Agents Chemother. 2014;58(4):1977-86</RefSource><PMID Version="1">24419350</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2000 Mar 16;404(6775):293-6</RefSource><PMID Version="1">10749213</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2017 Feb 1;74(2):229-241</RefSource><PMID Version="1">27749600</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell Stem Cell. 2014 Mar 6;14 (3):323-328</RefSource><PMID Version="1">24529597</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 2014 Nov 28;346(6213):1258096</RefSource><PMID Version="1">25430774</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>IDrugs. 2009 Dec;12(12):774-8</RefSource><PMID Version="1">19943220</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Nanomedicine. 2014 Apr 07;9:1757-69</RefSource><PMID Version="1">24741312</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell Regen (Lond). 2013 Jun 18;2(1):5</RefSource><PMID Version="1">25408877</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Ther Nucleic Acids. 2014 Jul 29;3:e178</RefSource><PMID Version="1">25072692</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>RNA Biol. 2005 Jan;2(1):17-20</RefSource><PMID Version="1">17132935</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2014 Jul 19;384(9939):258-71</RefSource><PMID Version="1">24907868</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Chemistry. 2011 Mar 7;17(11):3054-62</RefSource><PMID Version="1">21341332</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nucleic Acids Res. 2015 Jun 23;43(11):5560-71</RefSource><PMID Version="1">25964300</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nucleic Acids Res. 2016 Aug 19;44(14 ):6505-17</RefSource><PMID Version="1">27060137</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Pathog. 2015 Sep 17;11(9):e1005142</RefSource><PMID Version="1">26379282</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Virol. 2007 May;81(10):5121-31</RefSource><PMID Version="1">17360756</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Virol J. 2012 Nov 15;9:272</RefSource><PMID Version="1">23153325</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Viruses. 2013 Nov 14;5(11):2748-66</RefSource><PMID Version="1">24284874</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS Rev. 2005 Jan-Mar;7(1):22-5</RefSource><PMID Version="1">15875658</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2012 Jul 25;487(7408):482-5</RefSource><PMID Version="1">22837004</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):e17-24</RefSource><PMID Version="1">23756374</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Cell. 2015 May 21;58(4):568-74</RefSource><PMID Version="1">26000842</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Front Microbiol. 2016 Jun 28;7:1001</RefSource><PMID Version="1">27446041</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antiviral Res. 2011 Jan;89(1):43-53</RefSource><PMID Version="1">21093490</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Part Fibre Toxicol. 2010 Mar 03;7:3</RefSource><PMID Version="1">20199661</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Opin HIV AIDS. 2015 Mar;10(2):123-7</RefSource><PMID Version="1">25612322</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2011 Jan 4;108(1):409-14</RefSource><PMID Version="1">21173264</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Adv Drug Deliv Rev. 2015 Jun 29;87:52-67</RefSource><PMID Version="1">25747758</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hum Gene Ther. 2015 Oct;26(10 ):664-79</RefSource><PMID Version="1">26076730</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell. 2013 Oct 24;155(3):540-51</RefSource><PMID Version="1">24243014</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Biotechnol. 2011 Feb;29(2):143-8</RefSource><PMID Version="1">21179091</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Nanomedicine. 2016 Sep 01;11:4317-25</RefSource><PMID Version="1">27621624</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2005 Mar 1;191(5):654-65</RefSource><PMID Version="1">15688278</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Ther. 2013 Jun;21(6):1259-69</RefSource><PMID Version="1">23587921</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Genome Med. 2015 Aug 27;7:93</RefSource><PMID Version="1">26307031</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Biotechnol. 2016 Jul;34(7):768-73</RefSource><PMID Version="1">27136078</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2015 Mar 31;112(13):4038-43</RefSource><PMID Version="1">25775608</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Virology. 2013 Jan 5;435(1):102-9</RefSource><PMID Version="1">23217620</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Immunol. 2015 Jun;16(6):584-9</RefSource><PMID Version="1">25990814</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2015 Jul 23;523(7561):481-5</RefSource><PMID Version="1">26098369</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Methods. 2012 Jul 01;9(8):805-7</RefSource><PMID Version="1">22751204</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Mol Biol. 2006 Jul 21;360(4):760-73</RefSource><PMID Version="1">16793062</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Virology. 2014 Aug;462-463:328-39</RefSource><PMID Version="1">25014309</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurobiol Dis. 2016 Aug;92(Pt B):137-43</RefSource><PMID Version="1">26851503</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Genet. 2011 Feb;12(2):99-110</RefSource><PMID Version="1">21245828</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2002 Dec 6;16(18):2385-90</RefSource><PMID Version="1">12461411</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Biotechnol. 2008 Jul;26(7):808-16</RefSource><PMID Version="1">18587387</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2002 Oct 24;347(17):1364-7</RefSource><PMID Version="1">12397198</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>F1000Res. 2016 May 26;5:null</RefSource><PMID Version="1">27303638</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS Res Hum Retroviruses. 2006 May;22(5):401-10</RefSource><PMID Version="1">16706616</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Front Physiol. 2013 Aug 27;4:223</RefSource><PMID Version="1">23986717</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Retrovirology. 2009 Feb 04;6:11</RefSource><PMID Version="1">19193229</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 1997 Nov 14;278(5341):1291-5</RefSource><PMID Version="1">9360926</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Virol. 2017 Mar;162(3):793-798</RefSource><PMID Version="1">27888407</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Med Chem. 2014;21(36):4186-98</RefSource><PMID Version="1">25174930</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Sci Rep. 2014 Sep 18;4:6409</RefSource><PMID Version="1">25230987</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Virol. 2017 May 12;91(11):</RefSource><PMID Version="1">28356533</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antiviral Res. 2016 Feb;126:90-8</RefSource><PMID Version="1">26718067</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2002 Jul 25;418(6896):435-8</RefSource><PMID Version="1">12087358</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Mol Cell Biol. 2013 Jan;14(1):49-55</RefSource><PMID Version="1">23169466</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr HIV/AIDS Rep. 2010 Feb;7(1):37-43</RefSource><PMID Version="1">20425056</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 2016 Feb;126(2):448-54</RefSource><PMID Version="1">26731470</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Insect Mol Biol. 2017 Apr;26(2):127-139</RefSource><PMID Version="1">27991710</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Gene Ther. 2003 Nov;10(24):2046-50</RefSource><PMID Version="1">14566364</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Med. 2016 Aug;22(8):839-50</RefSource><PMID Version="1">27400264</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochem Biophys Res Commun. 2015 Apr 3;459(2):288-93</RefSource><PMID Version="1">25727021</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>FEBS J. 2015 Nov;282(22):4289-94</RefSource><PMID Version="1">26290158</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell. 2016 May 5;165(4):949-62</RefSource><PMID Version="1">27114038</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr HIV Res. 2010 Sep;8(6):418-29</RefSource><PMID Version="1">20636281</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hum Genet. 2016 Sep;135(9):1071-82</RefSource><PMID Version="1">27272125</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell Res. 2015 Jul;25(7):767-8</RefSource><PMID Version="1">26032266</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Chem. 2012 Sep;4(9):705-10</RefSource><PMID Version="1">22914190</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Immunol Cell Biol. 2015 Nov;93(10):896-908</RefSource><PMID Version="1">26027856</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Expert Opin Biol Ther. 2010 Feb;10(2):201-13</RefSource><PMID Version="1">20088715</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2007 Jun 15;195(12):1762-4</RefSource><PMID Version="1">17492591</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochemistry. 2014 Mar 11;53(9):1466-76</RefSource><PMID Version="1">24506064</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2012 Sep 1;206(5):765-9</RefSource><PMID Version="1">22732922</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Med. 1999 Jun;5(6):651-5</RefSource><PMID Version="1">10371503</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Ther. 2010 Nov;18(11):2028-37</RefSource><PMID Version="1">20648001</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Bioorg Med Chem Lett. 2017 Jan 15;27(2):121-130</RefSource><PMID Version="1">27956345</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Gen Virol. 2013 Dec;94(Pt 12):2587-98</RefSource><PMID Version="1">24026671</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Pathog. 2015 Jul 30;11(7):e1005063</RefSource><PMID Version="1">26225566</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Org Lett. 2014 Oct 3;16(19):5136-9</RefSource><PMID Version="1">25238583</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Pharm. 2015 Dec 7;12(12):4175-87</RefSource><PMID Version="1">26524196</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 2009 Oct;119(10):3035-47</RefSource><PMID Version="1">19741300</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Viruses. 2013 Nov 22;5(11):2898-919</RefSource><PMID Version="1">24284880</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2016 Aug 08;536(7615):136-7</RefSource><PMID Version="1">27510204</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Ther. 2014 Jun;22(6):1084-95</RefSource><PMID Version="1">24662946</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2008 Sep 05;3(9):e3146</RefSource><PMID Version="1">18773076</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Opin Plant Biol. 2010 Aug;13(4):394-401</RefSource><PMID Version="1">20570209</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trends Pharmacol Sci. 2007 Oct;28(10 ):526-35</RefSource><PMID Version="1">17888520</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2010 Jul 3;376(9734):49-62</RefSource><PMID Version="1">20609987</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Virol. 2014 Sep 1;88(17):9704-17</RefSource><PMID Version="1">24942577</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Gene Ther. 2011 Dec;18(12):1134-8</RefSource><PMID Version="1">21956690</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2006 Nov 15;108(10):3305-12</RefSource><PMID Version="1">16857988</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Gene Ther. 2016 Jul;23(7):627-33</RefSource><PMID Version="1">27052803</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Retrovirology. 2016 May 27;13(1):37</RefSource><PMID Version="1">27230886</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nucleic Acids Res. 2013 Mar 1;41(5):e63</RefSource><PMID Version="1">23275534</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Genome Med. 2015 May 28;7(1):50</RefSource><PMID Version="1">26019725</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2009 Aug 24;23(13):1743-53</RefSource><PMID Version="1">19571723</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 2013 Feb 15;339(6121):819-23</RefSource><PMID Version="1">23287718</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Ther Methods Clin Dev. 2015 Jan 14;1:14057</RefSource><PMID Version="1">26052525</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>RNA Biol. 2011 Nov-Dec;8(6):1035-46</RefSource><PMID Version="1">21955498</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2014 May 14;9(5):e97257</RefSource><PMID Version="1">24827152</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Virol. 2002 Aug;76(16):8118-23</RefSource><PMID Version="1">12134017</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Retrovirology. 2004 Dec 15;1:44</RefSource><PMID Version="1">15601474</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Pathog. 2013;9(12):e1003834</RefSource><PMID Version="1">24385908</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 1997 May 8;387(6629):188-91</RefSource><PMID Version="1">9144290</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Ther. 2013 Jan;21(1):192-200</RefSource><PMID Version="1">23164935</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Annu Rev Biochem. 2010;79:213-31</RefSource><PMID Version="1">20192761</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Exp Hematol. 2008 Jul;36(7):823-31</RefSource><PMID Version="1">18394775</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Virol. 2005 Sep;79(17):10999-1013</RefSource><PMID Version="1">16103151</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Immunity. 2012 Mar 23;36(3):491-501</RefSource><PMID Version="1">22406268</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Peptides. 2017 Jan;87:50-63</RefSource><PMID Version="1">27887988</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2014 Jul 17;28(11):1555-66</RefSource><PMID Version="1">24804860</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trends Pharmacol Sci. 2017 Apr;38(4):406-424</RefSource><PMID Version="1">28209404</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Antimicrob Chemother. 2014 Feb;69(2):404-15</RefSource><PMID Version="1">24022068</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Ther. 2006 Dec;14(6):883-92</RefSource><PMID Version="1">16959541</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell. 2015 Oct 22;163(3):759-71</RefSource><PMID Version="1">26422227</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Virol. 2005 Mar;79(5):3139-45</RefSource><PMID Version="1">15709033</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Control Release. 2016 Aug 10;235:14-23</RefSource><PMID Version="1">27235976</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Yale J Biol Med. 2011 Sep;84(3):301-9</RefSource><PMID Version="1">21966049</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Pharmacol. 2014 Sep;171(17):3963-79</RefSource><PMID Version="1">24467481</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Drug Targets. 2012 Oct;13(11):1411-20</RefSource><PMID Version="1">22664094</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Yi Chuan. 2016 Jan;38(1):9-16</RefSource><PMID Version="1">26787519</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet HIV. 2015 Dec;2(12 ):e520-9</RefSource><PMID Version="1">26614966</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 1999 Dec 3;13(17):2405-10</RefSource><PMID Version="1">10597782</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Control Release. 2017 Mar 28;250:62-76</RefSource><PMID Version="1">28167286</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2014 Dec 26;9(12):e115987</RefSource><PMID Version="1">25541967</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>01</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>05</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28705213</ArticleId><ArticleId IdType="doi">10.1186/s12981-017-0157-8</ArticleId><ArticleId IdType="pii">10.1186/s12981-017-0157-8</ArticleId><ArticleId IdType="pmc">PMC5513397</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000571 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000571 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:28705213
|texte= The therapeutic landscape of HIV-1 via genome editing.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:28705213" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SidaGhanaV1
| This area was generated with Dilib version V0.6.31. |  |